Last €29.50 EUR
Change Today 0.00 / 0.00%
Volume 0.0
As of 6:52 AM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

stada arzneimittel ag-new (SAZN) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/2/15 - €29.50
52 Week Low
01/5/15 - €25.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

stada arzneimittel ag-new (SAZN) Related Businessweek News

No Related Businessweek News Found

stada arzneimittel ag-new (SAZN) Details

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. The company operates primarily in two segments, Generics and Branded Products. The Generics segment provides various active ingredients, including stomach medicines, antihypertensive agents, and anti-inflammatory agents. This segment’s primarily products include Phospholipide, a liver medicine; Diclofenac, an antirheumatic drug; Tilidine, an opioid; Enalapril, an ACE inhibitor; and Omeprazole, a stomach medicine. The Branded Products segment offers non-prescription products, such as Grippostad and Ladival. This segment’s products also comprise Apo-Go, a Parkinson medicine; Snup, a nasal preparation; Zaldiar, a pain medicine; Chondroxid for the treatment of degenerative joint diseases; and Ladival, a sun cream. The company has license and collaboration agreements with Gedeon Richter Plc for the development and marketing of biosimilar products for two monoclonal antibodies rituximab and optionally trastuzumab. It serves patients and/or consumers, doctors, doctors’ cooperatives, pharmacies, pharmacy co-operatives, hospitals, wholesalers, and other service providers in the health care market, as well as public health insurance organizations or private insurances. STADA Arzneimittel Aktiengesellschaft was founded in 1895 and is headquartered in Bad Vilbel, Germany.

9,825 Employees
Last Reported Date: 03/26/14
Founded in 1895

stada arzneimittel ag-new (SAZN) Top Compensated Officers

Chairman of the Executive Board and Chief Exe...
Total Annual Compensation: €3.2M
Chief Financial Officer and Member of Executi...
Total Annual Compensation: €1.4M
Chief Business Development & Central Services...
Total Annual Compensation: €844.6K
Compensation as of Fiscal Year 2013.

stada arzneimittel ag-new (SAZN) Key Developments

Stada-Arzneimittel Ag Provides Unaudited Preliminary Earnings Guidance for the Year 2014 and 2015; Provides Dividend Guidance for Fiscal 2014

Stada-Arzneimittel AG provided unaudited preliminary earnings guidance for the year 2014. Group sales is expected to have risen by 3% to €2,062.2 million; Reported EBITDA is expected to have increased by 9% to €418.8 million; adjusted EBITDA is anticipated to have increased by 4% to €431.9 million. Overall, there were one-time special effects in the expected amount of €128.6 million before or €121.6 million after taxes. They include impairments on goodwill in the expected amount of €54.0 million before and after taxes as well as on further intangible assets in the expected amount of €22.0 million before and €21.7 million after taxes as a result of the significantly changed interest rate and currency environment as well as ongoing higher risks in the market region CIS/Eastern Europe. In light of this, reported net income is expected to have decreased by 47% to €64.6 million; Adjusted net income is anticipated to have increased by 16% to €186.2 million. Reported earnings per share are anticipated to have decreased to €1.07; and Adjusted earnings per share are expected to have increased to €3.08. As of the balance sheet date, net debt is expected to amount to €1,327.5 million; Cash flow from operating activities is expected to have amounted to €223.8 million in financial year 2014; Free cash out flow is anticipated to have amounted to €38.2 million; Free cash flow adjusted for payments for significant investments or acquisitions and proceeds from significant disposals is expected to have amounted to €157.4 million. For the preliminary outlook for 2015, the Executive Board currently anticipates growth in Group sales adjusted for currency and portfolio effects. From today's perspective, the Executive Board however expects a decreased earnings contribution from Russia due to the recent developments of the Russian ruble and increased risks in connection with consumer mood and the general market situation. Taking these developments into account and based on current currency relations, the Executive Board expects from the current perspective a substantial decrease in adjusted EBITDA and adjusted net income. Due to the decreased net income reported, the STADA Executive Board recommends that the Supervisory Board propose to the next Annual General Meeting on June 3, 2015 an unchanged dividend of €0.66 per common share for financial year 2014 against €0.66 for the last year. The resulting total dividend payment of €40.0 million reflects a significantly higher distribution ratio than the previous year at approximately 62% of net income reported.

Stada-Arzneimittel AG Presents at UniCredit und Kepler Cheuvreux 14th German Corporate Conference, Jan-19-2015 10:45 AM

Stada-Arzneimittel AG Presents at UniCredit und Kepler Cheuvreux 14th German Corporate Conference, Jan-19-2015 10:45 AM. Venue: Villa Kennedy, Kennedyallee 70, D-60596 Frankfurt, Germany. Speakers: Helmut Kraft, Chief Financial Officer and Member of Executive Board.

Stada-Arzneimittel AG Presents at Oddo Midcap Forum, Jan-08-2015 through Jan-09-2015

Stada-Arzneimittel AG Presents at Oddo Midcap Forum, Jan-08-2015 through Jan-09-2015. Venue: Lyon’s Convention Center, Lyon, France. Presentation Date(s): Jan-08-2015. Jan-09-2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SAZN:GR €29.50 EUR 0.00

SAZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Richter Gedeon Nyrt 3,800 -130.00
Impax Laboratories Inc $40.45 USD +0.16
Oxford Biomedica PLC 8.18 GBp +0.225
Skyepharma PLC 307.00 GBp -0.50
Vernalis PLC 47.00 GBp -0.62
View Industry Companies

Industry Analysis


Industry Average

Valuation SAZN Industry Range
Price/Earnings 12.2x
Price/Sales 0.8x
Price/Book 1.6x
Price/Cash Flow 12.1x
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STADA ARZNEIMITTEL AG-NEW, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at